CRAiN artificial intelligence
Today we live in a knowledge economy. Knowledge is abundant and available/accessible. We consult various databases to retrieve relevant information from different sources. It’s like brainstorming with the world.
CRAiN stands for Creax brain and AI for Artificial Intelligence. Our multi-source CRAiN platform structures the chaos of worldwide data and digests it into comprehensible information and insights.
We recycle and transfer existing knowledge across industries. Our AI enabled text-mining platform retrieves relevant data from different sources, covering the entire technology lifecycle.
Good decisions are based on insights
As a decision maker, you have to make critical choices. But how do you make strategic innovation decisions in this fast-moving world? A world with abundant knowledge which, contradictory, is often overwhelming
No-one can study everything
The answers are out there, but finding the information you need is not easy. It can feel like finding a needle in a haystack: difficult and very time consuming.
This is where CRAiN comes in. Our multi-source artificial intelligence platform extracts structure and comprehensible information out of the chaos of data.
Combining human and artificial intelligence
In our acclaimed systematic approach a multidisciplinary team, assisted by a datamining platform, sifts through huge amounts of worldwide knowledge and experience. This exhaustive research confirms the known and charts the unknown into an applicable outline. A blueprint for a risk-free innovation strategy.
Complete, unbiased and fast.
Fast & efficient
Nowadays, living in the knowledge economy, information is accessible in huge amounts. CRAiN analyzes a variety of structured and unstructured data sources, such as literature, patents, material databases, medical databases, start-up databases, consumer forums, etc. to cover the entire lifecycle of technologies. This way, we gain complete strategic insights concerning technology and market information, in a fast and efficient way.
Classically, research is done bottom-up, starting from what is known. The CREAX approach is top-down, starting from all possible relevant information. By hiding unrelevant aspects, we deep-dive systematically into the desired topics.
Every problem has already been solved by someone. That’s why efficient innovation starts with researching existing
knowledge across industries and domains. When learning from existing solutions, the wheel is not reinvented, and the risk factor related to innovation is reduced subsequently. And we save precious time. Creax wondered in what extend this philosophy is being applied for dealing with the corona crisis.
The COVID-19 (coronavirus disease 2019) pandemic we are facing right now is caused by a coronavirus which is related (about 79% genetic similarity)  to the virus that caused the SARS (severe acute respiratory syndrome) epidemy in the 2000s. The virus belongs to the species SARS-related coronavirus (SARS-CoV) and has been named SARS-CoV-2 . Thanks to the similarity with the SARS coronavirus (SARS-CoV or SARS-CoV-1), and other SARS-related coronaviruses (SARSr-CoVs), previous scientific research on these viruses could provide valuable insights for the COVID-19 pandemic. Therefore, creax analysed a pool of peer-reviewed scientific documents mentioning SARS-CoV-1 or SARSr-CoVs and SARS-CoV-2. The goal is to reveal possible patterns in the responses of the scientific and industrial community to these outbreaks, and to extract potential implementations of previous learning into the COVID-19 context.
The scientific community is responding very fast to the COVID-19 pandemic.
To get an overview of the topics discussed in these scientific publications, the document pool was analysed by the creax team, supported by its in-house developed (con)text-mining platform CRAiN. CRAiN offers the possibility to get profound insights in a big collection of text documents from various sources. The software allows to create an unbiased, detailed and at the same time exhaustive view about a scientific or technological domain. This results in learnings about trends, emerging technology developments, important applications, white space opportunities, etc… It is applicable for both experts in their fields as for people/companies that want to discover a domain without having any knowledge or experience.
A first outcome of the CRAiN analysis is a field map (figure 3). This field map visualizes the clustering of documents that discuss similar topics. Each circle represents a specific field of interest. The annotation of each circle describes the keyword(s) relevant to this field. What can we learn from this graph?
The size of the circle indicates how many articles are linked to the field. The colouring of the circle is linked to papers discussing SARS-CoV-1 (cyan) and SARS-Cov-2 (yellow). Interesting are the green overlaps. These indicate an activity field in which learnings from the previous SARS outbreak are discussed in function of current scientific research about COVID-19. The proximity of the bubbles indicates how closely related topics are. As such we can allocate different groups to different bigger domains of interests.
In the lower part of the map a higher percentage of papers about SARS-CoV-2 is seen. Almost all these papers discuss the
epidemiology, disease control, and diagnosis of COVID-19. This is not surprising as in response to a fast evolving pandemic, like COVID-19, priority focus is laid on monitoring the infection rate and spread, methodologies to reduce the impact of the infection (e.g. flatten the curve) and diagnosing the disease through a fast, sensitive and reliable test.
First responses to the COVID-19 pandemic are focusing on
1) monitoring the spread of the virus,
2) strategies to reduce the spread of the virus, and
3) development of diagnostic tests.
Researchers are clearly looking to
learn from previous virus outbreaks. As an example, in the right part of the field map a big cluster about “Middle East respiratory syndrome (MERS), MERS-CoV” is detected. Close to this field, fields about ‘beta and alpha-coronavirus’ and ‘phylogenetic evolution’ are found. Hence, scientific papers connecting these fields of interest focus on the genetic relationship between viruses and research groups learn from that.
rely on established strategies. Amongst others, a big field of interest in the left corner of the field map is about 3CLpro protease, which is a family of enzymes that plays a role in the replication of coronaviruses. The field does not seem to be populated by a lot of articles about SARS-CoV-2. However, because of the low threshold of the CRAiN platform, a preprint paper by Stoermer et al. was found that states that 3CLpro protease of SARS-CoV-2 is for 96% identical to the 3CLpro protease of SARS-CoV-1. Inhibitors previously developed for the SARS-Cov-1 variant potentially could be used to inhibit the reproduction of SARS-CoV-2 and thus in the treatment of COVID-19. Natural polyphenols have been mentioned in this context as suspected to be more effective than e.g. nelfinavir.
Researchers learn from previous virus outbreaks and rely on established strategies to treat for COVID-19 that are sometimes based on natural products.
As informative the individual fields are, novel solutions can sometimes be found
out domain through associations between fields. As referred to in the beginning of this blog, researchers do not always need to reinvent the wheel. Let’s take the ‘MERS’ cluster as an example (figure 4). This cluster links fields about virus families, their originating animals (e.g. pangolin, horseshoe bat, ferret, etc.) and regions, and therapeutic strategies. One interesting associated field is the one marked in yellow in figure 4 (‘Nucleotide analogues’). In this field a preliminary research activity was found about the use of nucleotide analogues to inhibit RNA-dependent RNA polymerase (RdRp), which is also relevant for SARS-CoV-2. These broad-spectrum nucleotide analogues have shown to be effective for SARS-CoV-1 before and it has been suggested to develop a therapeutic for SARS-CoV-2 based on these compounds. A potential nucleotide analogue drug in the battle against COVID-19 might be based on the FDA-approved heptatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) developed by the pharmaceutical company Gilead Sciences.
Despite not being an expert in each individual scientific field, creax is able to
discover and quantify in an unbiased way the scientific dynamics evolving since the COVID-19 outbreak, thanks to its in-house developed AI platform CRAiN. As such we have revealed that learnings about monitoring, limiting, diagnosis or therapies for SARS-CoV-2 are reused or used as inspiration in the current context.
The field maps shown in this blog are only the starting point for
deep-dive research. The CRAiN platform allows to filter out specific topics and categorize them accordingly, for example as therapeutic compounds, biological targets, target groups, etc. The combination of these specific types of information are a catalyst to efficient research roadmaps.
The creax team is available to answer your specific interests about this research and discuss potential requests for deep-dive analysis of interest areas. Please find our contact details below.
Download this paper and the high-resolution pictures of the field map
The text and images have been created by creax. The content shown is property of creax and should not be replicated without mentioning creax as source. Copyright 2020 – All rights reserved.
Creax is a research-driven innovation advice bureau. As an innovation expert, Creax can draw on experience and expertise acquired during the past 20 years in more than 1,250 projects in a wide range of sectors. Through a process of AI-aided research in various databases and other knowledge sources, we are able to create cross-industry intelligence. The insights and recommendations obtained in this manner form the basis for strategic decisions and the development of groundbreaking innovative solutions.
Contact: Mathieu Mottrie – CEO – firstname.lastname@example.org – +32 56 23 94 94
 Figure 1 Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395:565–74.
 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5.
 Kim Y, Lovell S, Tiew K-C, Mandadapu SR, Alliston KR, Battaile KP, Groutas WC, Chang K-O. Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses. J Virol 2012; 86:11754–62.
 Stoermer M. Homology Models of Coronavirus 2019-nCoV 3CLpro Protease. ChemRxiv 2020;
 Adem S, Eyupoglu V, Sarfraz I, Rasul A, Ali M. Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: An in silico strategy unveils a hope against CORONA. 2020; :1–29.
 Ju J, Kumar S, Li X, Jockusch S, Russo JJ. Nucleotide Analogues as Inhibitors of Viral Polymerases. bioRxiv 2020; 1:2020.01.30.927574.
Want to know more?
Wondering how Creax extracts actionable insights from globally distributed information?